Liver cancer is the fourth leading cause of cancer-related death globally and its incidence is growing with estimates of over a million cases per year by 2025 [62]; however, a mass screening trial for liver cancer in China using serum alpha-fetoprotein and ultrasonography did not yield a reduction in liver cancer-specific mortality [63]. This evidence concerns the gene AFP and liver cancer.